Skip to content
Apnimed
Open Menu
  • HOME
  • About
    • Our Story
    • Leadership
    • Contact
  • Our Focus
    • Obstructive Sleep Apnea
    • Pipeline
    • Clinical Trials
    • Scientific Publications
  • AD109
  • OSA Stories + Community
  • Careers
  • News

BTIG Virtual Biotechnology Conference 2025

Positive Phase 3 Data for AD109 from Second Pivotal Trial

Read More

Apnimed Unveils Topline Data from Second Phase 3 Trial of AD109, Validating Efficacy and Impact for OSA.

Read More
A in Apnimed

It’s our goal to elevate treatment for people with OSA—subscribe for updates.

Contact Us

This field is for validation purposes and should be left unchanged.
NYSE: [SYMBOL]
$xxx.xx
+1.20 (0.5%)
Last updated: 7/03/2024 12:11 PM
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Cookie Settings
Follow Us
NYSE: [SYMBOL]
$xxx.xx
+1.20 (0.5%)
Last updated: 7/03/2024 12:11 PM

©2024 Apnimed, Inc. All rights reserved. Apnimed is a Cambridge, MA-based clinical stage company dedicated to the discovery of novel therapies for sleep apnea and related disorders. The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.